Art. -Nr.: HY-181442

CK2-TN03

Kundenbewertung

Based on 1 Customer Validation

CK2-TN03 is an ATP-competitive casein kinase 2 (CK2) inhibitor, with an IC₅₀ of 165 nM and a K_i of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1. CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin, leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.02%
CAS. Nr.: 313226-24-3
Formel: C₁₇H₁₄N₂O₃S
Molecular Weight:326.37

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

CK2-TN03 Chemical Structure

CAS. Nr.: 313226-24-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

CK2

165 nM (IC₅₀)

Caspase 3

Caspase-7

BRD4

Akt1

Alle Casein Kinase Isoform-spezifische Produkte anzeigen :

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

In Vitro

CK2-TN03 (0.2-25.0 μM; 48 h) induces dose-dependent cell death in the medulloblastoma DAOY cell line and multiple neuroblastoma cell lines, with EC₅₀ values ranging from 0.31 to 1.95 μM; it shows no activity in glioblastoma U87 cells (EC₅₀ >25 μM)^[1].
CK2-TN03 (0.35-1.0 μM; 48 h) activates caspase 3/7 in CHP-212 neuroblastoma cells in a time-dependent manner, and primarily induces caspase-dependent apoptosis^[1].
CK2-TN03 (0.5-1.0 μM; 24-48 h) induces G2/M cell cycle arrest and subsequent cell death in CHP-212 neuroblastoma cells^[1].
CK2-TN03 (0.5 μM; 24 h) arrests CHP-212 neuroblastoma cells in mitosis, blocks successful cell division, and induces mitotic catastrophe and cell death^[1].
CK2-TN03 (0.5 μM; 48 h) downregulates the activity and expression of survivin in CHP-212 neuroblastoma cells by directly inhibiting CK2-mediated phosphorylation of survivin and indirectly altering the AKT1/MDM2/p53 and BRD4/MYCN pathways, without changing the expression of CK2^[1].
CK2-TN03 (0.5 μM; 48 h) does not affect the viability of differentiated quiescent SH-SY5Y neuroblastoma cells, which exhibit low survivin expression levels^[1].
CK2-TN03 (1-10 μM; 72 h) induces cell death in a diverse panel of 160 cancer cell lines, with significant tumor entity selectivity, and exhibits the highest potency against melanoma, lymphoma, lung cancer, neuroblastoma, ovarian cancer, myeloma, soft tissue cancer and osteosarcoma cell lines^[1].
CK2-TN03 (10 μM; 1 h) exhibits excellent permeability in MDCKII-MDR1 cells, with negligible efflux and no P-gp substrate activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

Neuroblastoma CHP-212
Concentration:

0.35, 0.5 and 1.0 μM
Incubation Time:

48 h (monitored every 2 h)
Result:

Induced a time-dependent increase in caspase 3/7 activation, with significantly higher activation levels observed from 18 h onward compared to vehicle-treated controls.
Left a fraction of cell death unaffected by cotreatment with pan-caspase inhibitor Q-VD-OPh, while the inhibitor reduced most CK2-TN03-induced cell death.

Cell Cycle Analysis^[1]

Cell Line:

Neuroblastoma CHP-212
Concentration:

0.5 and 1.0 μM
Incubation Time:

24 h, 48 h
Result:

Increased the percentage of cells in the G2/M phase and the subG1 (dead cell) population after 24 and 48 h of treatment, with significant increases observed at both concentrations and time points compared to controls.
Increased G2/M phase cells after 24 h at 0.5 μM and 1.0 μM.
Further elevated G2/M and subG1 populations after 48 h at both concentrations.

Cell Viability Assay^[1]

Cell Line:

Differentiated neuroblastoma SH-SY5Y
Concentration:

0.5 μM
Incubation Time:

48 h
Result:

Did not reduce viability of differentiated SH-SY5Y cells, which had ~20% of the survivin protein levels present in undifferentiated cells.

In Vivo

CK2-TN03 (40 mg/kg; i.p.; once daily; 28 days) significantly reduces neuroblastoma xenograft tumor growth and improves mouse survival, with a subset of mice achieving long-term tumor control or remission^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

(Ncr)-Foxn1 nu nude mice (7-8 weeks old)^[1]
Dosage:

40 mg/kg
Administration:

i.p.; once daily; 28 days
Result:

Reduced tumor growth rate, with tumor volume relative to baseline (VTx/VT0) reaching ~6 on day 28, compared to ~9 in vehicle controls.
Improved mouse survival: 5 treated mice survived to day 49, compared to 1 vehicle-treated mouse; 2 treated mice survived beyond day 85, with one showing complete tumor remission by day 14 and the other exhibiting a small, non-growing tumor mass post-treatment.
Increased p53 levels and decreased survivin levels and survivin phosphorylation in tumor tissue.

Chemical Information

CAS. Nr. 313226-24-3
Appearance Solid
Molecular Weight 326.37
Formel C₁₇H₁₄N₂O₃S
Color Light yellow to yellow
SMILES

COC(C=C1)=C(O)C=C1/C=C(C(N/2)=O)/SC2=N\C3=CC=CC=C3
Sequence

Asp-Lys-Phe-Val-Gly-{Leu-methyl}-{Nle}-NH2
Sequence Shortening

DKFVG-{Leu-methyl}-{Nle}-NH2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 83.33 mg/mL (255.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0640 mL

15.3200 mL

30.6401 mL

5 mM

0.6128 mL

3.0640 mL

6.1280 mL

10 mM

0.3064 mL

1.5320 mL

3.0640 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cazzanelli G, et al. Switching off CK2-mediated activation of survivin offers new therapeutic opportunities in neuroblastoma. Exp Mol Med. 2026;58(1):227-242. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0640 mL	15.3200 mL	30.6401 mL	76.6002 mL
	5 mM	0.6128 mL	3.0640 mL	6.1280 mL	15.3200 mL
	10 mM	0.3064 mL	1.5320 mL	3.0640 mL	7.6600 mL
	15 mM	0.2043 mL	1.0213 mL	2.0427 mL	5.1067 mL
	20 mM	0.1532 mL	0.7660 mL	1.5320 mL	3.8300 mL
	25 mM	0.1226 mL	0.6128 mL	1.2256 mL	3.0640 mL
	30 mM	0.1021 mL	0.5107 mL	1.0213 mL	2.5533 mL
	40 mM	0.0766 mL	0.3830 mL	0.7660 mL	1.9150 mL
	50 mM	0.0613 mL	0.3064 mL	0.6128 mL	1.5320 mL
	60 mM	0.0511 mL	0.2553 mL	0.5107 mL	1.2767 mL
	80 mM	0.0383 mL	0.1915 mL	0.3830 mL	0.9575 mL
	100 mM	0.0306 mL	0.1532 mL	0.3064 mL	0.7660 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CK2-TN03

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Alle Casein Kinase Isoform-spezifische Produkte anzeigen

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CK2-TN03 Related Classifications

HY-181442 Related Classifications